May 7, 2019 / 5:09 AM / 2 months ago

BRIEF-Roche to include new SMA drug data in U.S., Europe filings set for H2 2019

May 7 (Reuters) - Roche Holding AG:

* SAYS IN THE DOSE-FINDING PART 1 OF FIREFISH STUDY, INFANTS WITH TYPE 1 SPINAL MUSCULAR ATROPHY SURVIVED AND ACHIEVED MILESTONES BEYOND THOSE EXPECTED IN NATURAL HISTORY OF DISEASE

* SAYS IN FIREFISH STUDY, 10 OUT OF 17 INFANTS IN THE THERAPEUTICALLY DOSED GROUP ACHIEVED A CHOP-INTEND TOTAL SCORE OF 40 POINTS OR MORE, MEDIAN CHANGE FROM BASELINE TO MONTH 12 IN CHOP-INTEND WAS 17.5 PTS

* SAYS PLANS TO INCLUDE NEW DATA PRESENTED AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING IN REGULATORY FILINGS IN U.S., EUROPE DURING THE SECOND HALF OF 2019 Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below